Table 1.
Baseline characteristics.
| Chemotherapy-Naïve (n = 1562) |
Post-Chemotherapy (n = 621) |
|
|---|---|---|
| Characteristic | ||
| Age, years; mean (SDev) | 78 (8.1) | 73 (8.0) |
| Rural | 32.2 | 33.8 |
| Time from PCa dx to index, years; mean (SDev) | 8.1 (5.6) | 7.2 (5.1) |
| Prior local PCa treatment | 39.1 | 43.6 |
| Symptomatic indicator | 41.1 | 52.0 |
| Bone-targeted therapy | 34.2 | 71.0 |
| Charlson index ≥ 4 | 6.7 | 5.6 |
| Hypertension | 70.5 | 67.2 |
| Dyslipidemia | 57.2 | 53.1 |
| Diabetes | 22.8 | 20.6 |
| Coronary artery disease | 14.5 | 14.2 |
| Myocardial infarction | 3.1 | 2.6 |
| Cerebrovascular disease | 2.8 | 1.3 |
| Heart failure | 4.9 | 2.9 |
| Arrhythmia | 12.5 | 9.0 |
| Peripheral artery disease | 5.1 | 4.8 |
| Venous thromboembolism | 2.9 | 4.4 |
| ≥1 cardiovascular condition | 28.1 | 25.8 |
| Renal disease | 9.9 | 7.7 |
| Liver disease | 1.7 | 0.7 |
| Nbr SPC visits; mean (SDev) | 13.8 (11.6) | 22.0 (11.0) |
| Hospital admission (≥1) | 41.8 | 45.7 |
| Nbr drug classes; mean (SDev) | 12.8 (5.2) | 14.5 (5.2) |
| Novel hormonal agent | ||
| ABI | 78.8 | 87.3 |
| ENZ | 22.2 | 12.7 |
| Prescribing specialty | ||
| Medical oncologist | 44.5 | 74.4 |
| Urologist | 41.6 | 14.7 |
| Other | 14.0 | 11.0 |
All numbers represent percentages unless otherwise noted. Abbreviations: Nbr = number; PCa = prostate cancer; SDev = standard deviation; SPC = specialist physician.